Overestimation of N-glycoPEGylated factor IX activity in a one-stage factor IX clotting assay owing to silica-mediated premature conversion to activated factor IX

Journal of Thrombosis and Haemostasis

Volumn 14, Issue 7, 2016, Pages 1420-1427

  Rosen P ^a   Rosen S ^a   Ezban, M ^b   Persson, E ^b  

^a Rossix   (Sweden)

^b NOVO NORDISK A S   (Denmark)

Author keywords

blood coagulation tests; coagulation factor IX; hemophilia B; nonacog beta pegol; silicon dioxide

Indexed keywords

BLOOD CLOTTING FACTOR 11A; BLOOD CLOTTING FACTOR 9A; MACROGOL; PLASMA KALLIKREIN; RECOMBINANT BLOOD CLOTTING FACTOR 9; SILICON DIOXIDE;

ARTICLE; BLOOD CLOTTING TEST; CONTROLLED STUDY; DRUG ACTIVATION; DRUG ADSORPTION; DRUG DETERMINATION; ONE STAGE FACTOR IX CLOTTING ASSAY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL;

EID: 84990224582     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.13359     Document Type: Article

References (14)

1. Oldenburg J, Albert T. Novel products for haemostasis – current status. Haemophilia 2014; 20(Suppl. 4): 23–8.
2. Peters RT, Low SC, Kamphaus GD, Dumont JA, Amari JV, Lu Q, Zarbis-Papastoitsis G, Reidy TJ, Merricks EP, Nichols TM, Bitonti AJ. Prolonged activity of factor IX as a monomeric Fc fusion protein. Blood 2010; 115: 2057–64.
3. Shapiro A, Ragni MV, Valentino LA, Key NS, Josephson NC, Powell JS, Cheng G, Thompson AR, Goyal J, Tubridy KL, Peters RT, Dumont JA, Euwart D, Li L, Hallén B, Gozzi P, Bitonti AJ, Jiang H, Luk A, Pierce GF. Recombinant factor IX–Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. Blood 2012; 119: 666–72.
4. Metzner HJ, Weimer T, Kronthaler U, Lang W, Schulte S. Genetic fusion to albumin improves the pharmacokinetic properties of factor IX. Thromb Haemost 2009; 102: 634–44.
5. Santagostino E, Negrier C, Klamroth R, Tiede A, Pabinger-Fasching I, Voigt C, Jacobs I, Morfini M. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood 2012; 120: 2405–11.
6. Østergaard H, Bjelke JR, Hansen L, Petersen LC, Pedersen AA, Elm T, Møller F, Hermit MB, Holm PK, Krogh TN, Petersen JM, Ezban M, Sørensen BB, Andersen MD, Agersø H, Ahmadian H, Balling KW, Christiansen MLS, Knobe K, Nichols TM, et al. Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide. Blood 2011; 118: 2333–41.
7. Negrier C, Knobe K, Tiede A, Giangrande P, Møss J. Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. Blood 2011; 118: 2695–701.
8. Brooks AR, Sim D, Gritzan U, Patel C, Blasko E, Feldman RI, Tang L, Ho E, Zhao X-Y, Apeler H, Murphy JE. Glycoengineered factor IX variants with improved pharmacokinetics and subcutaneous efficacy. J Thromb Haemost 2013; 11: 1699–706.
9. Kitchen S, Gray E, Mertens K. Monitoring of modified factor VIII and IX products. Haemophilia 2014; 20(Suppl. 4): 36–42.
10. Dodt J, Hubbard AR, Wicks SJ, Gray E, Neugebauer B, Charton E, Silvester G. Potency determination of factor VIII and factor IX for new product labelling and postinfusion testing: challenges for caregivers and regulators. Haemophilia 2015; 21: 543–9.
11. Holm PK, Sørensen MH, Hermit MB, Ezban M. The activity of glycoPEGylated recombinant FIX (N9-GP) can be measured in two-stage chromogenic and one-stage clotting assays. J Thromb Haemost 2013; 11(Suppl. 2): 828 (abstract PB3.49-1).
12. Lochu A, Romari N, Beltran J, Magdelaine A, Ezban M, Hermit MB. Influence of FIX and FVIII PEGylation on FIX and FVIII activity based on APTT assays. J Thromb Haemost 2013; 11(Suppl. 2): 970 (abstract PB4.54-1).
13. ®-based one-stage clot assay and in TEG assay using blood from hemophilia B patients. Haemophilia 2014; 20(Suppl. 3): 24 (abstract).
14. Sørensen MH, Andersen S, Ezban M. Factor IX-deficient plasma spiked with N9-GP behaves similarly to N9-GP post-administration clinical samples in N9-GP ELISA and FIX activity assays. Haemophilia 2015; 21: 832–6.